A 42-year-old executive sat in my office last fall, two years into trying to drink less. She had finished outpatient rehab. She had a sponsor. She wanted to stop, kept telling herself she was going to stop, and still found herself opening a bottle most evenings. She blamed her character. She apologized to her family. She did not believe a medication could touch what she was feeling.
A new trial in The Lancet suggests she may have been wrong.
What the Lancet Trial Found
Researchers at the University of Copenhagen ran a 26-week randomized, double-blind, placebo-controlled trial in 108 adults with moderate-to-severe alcohol use disorder and comorbid obesity. Half received once-weekly semaglutide at 2.4 mg subcutaneously, the dose used for obesity treatment. Half received saline placebo. Every participant got standard cognitive behavioral therapy on top of the injection.
Heavy drinking days dropped 41.1 percentage points from baseline in the semaglutide group, compared with 26.4 in the placebo group. The estimated treatment difference was 13.7 percentage points (p=0.0015). Total alcohol consumption fell by 1,550 grams per 30 days in the semaglutide arm versus 1,026 grams in placebo. The number needed to treat was 4.3. For comparison, the three FDA-approved AUD medications, naltrexone, acamprosate, and disulfiram, generally carry an NNT of 7 or higher.
That is not a marginal effect. That is a treatment effect that beat the standard of care in head-to-head terms, in a population conventional addiction medicine has been quietly failing for decades.
Why a Diabetes Drug Works on Alcohol
Semaglutide is a glucagon-like peptide-1 receptor agonist. It was developed for type 2 diabetes, then approved for obesity, and patients on it kept reporting something unexpected: they stopped wanting to drink. They stopped wanting to gamble. They stopped wanting to smoke. The pattern was so consistent that it forced the addiction medicine field to look at what GLP-1 receptors actually do in the brain.
The answer is mechanistic and important. GLP-1 receptors live in the ventral tegmental area and the nucleus accumbens, the same brain regions that fire when an alcoholic feels the pull of a drink. When semaglutide binds these receptors, it dampens dopamine release in the reward circuit. The neural craving signal goes quieter. The patient still has the option to drink. The brain just stops screaming for it.
This is the biological mechanism I have spent thirty years arguing for. Alcohol use disorder is not a character flaw. It is a malfunction in the brain's reward system, and when you treat the reward system, the behavior changes. It never was about willpower.
What This Means for the Way We Talk About Recovery
I have watched patients sit in twelve-step meetings and apologize for their disease for years. They internalize a story in which their drinking proves they are weak. Family members ask why they cannot stop. Employers fire them for relapses. Insurance companies cover detox but not the medications that would prevent the next one.
The semaglutide finding does something the field has needed for a long time. It puts hard randomized-trial numbers on a biological claim about addiction. When a 41 percent reduction in heavy drinking days is achieved with an injection that modulates dopamine signaling, the moral framing collapses. You cannot pray your dopamine receptors back into balance. You cannot white-knuckle a hypodopaminergic state. You can, however, treat it.
Reward deficiency syndrome, the framework that some of us have been working under for thirty years, finally has the kind of evidence that conventional medicine respects. The Lancet does not publish trials of pseudoscience. The number needed to treat does not lie.
What to Do With This Information
If you are in recovery or supporting someone who is, the practical implication is this: medication-assisted treatment for alcohol use disorder is no longer a fringe option. It is the front line of evidence-based care. The right question to ask a treatment program is not whether they offer abstinence-based counseling. The right question is whether they have a clinician who can assess you for GLP-1 candidacy, run the bloodwork, manage the side effects, and pair the pharmacology with the behavioral work.
This is exactly the gap that the Rescue From Rehab protocol at The Neurogenesis Project was built to close. Most patients arrive after one or more cycles of conventional rehab that focused on willpower and group support without ever addressing the underlying neurobiology. We start with the brain. We assess reward circuit function, metabolic health, nutritional deficiencies that worsen craving, and the genetic factors that make some patients more vulnerable to relapse. We then build a treatment plan that includes the pharmacology, the behavioral work, and the brain nutrition the patient has likely been missing.
For patients with comorbid obesity, the semaglutide pathway is now squarely on the table. For patients without obesity, the same neurobiological logic applies to a growing list of options, including low-dose naltrexone, supervised psilocybin protocols, targeted amino acid therapy through Action Potential Supplements, and structured neurocoaching that retrains the reward circuit through repeated successful exposure to non-substance reinforcement. Readers tracking the broader neurobiological case against the moral model may also want to read our companion piece on why addiction is brain failure, not moral failure.
The 42-year-old executive in my office did not have comorbid obesity, so semaglutide was not her answer. We treated her hypodopaminergic state through nutrition, sleep restoration, low-dose naltrexone, and weekly neurocoaching. She has not had a drink in eight months. She no longer apologizes for her brain. That second change is the one that matters most.
The Lancet has handed the addiction medicine field a number it cannot ignore: 4.3. The recovery community deserves clinicians who know what to do with it.